Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Autologous Costal Chondrocyte
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Clinical Trial of CartiLife® in Korea
Details : CartiLife (Autologous Costal Chondrocyte) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cartilage Diseases.
Product Name : CartiLife
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 21, 2021
Lead Product(s) : Autologous Costal Chondrocyte
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Autologous Costal Chondrocyte
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Clinical Trial of CartiLife® in the United States
Details : CartiLife (Autologous Costal Chondrocyte) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cartilage Diseases.
Product Name : CartiLife
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 09, 2021
Lead Product(s) : Autologous Costal Chondrocyte
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chondrocytes
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Recipient : Mundipharma
Deal Size : Undisclosed
Deal Type : Agreement
Mundipharma, Biosolution to market CartiLife in South Korea
Details : Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 06, 2020
Lead Product(s) : Chondrocytes
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Recipient : Mundipharma
Deal Size : Undisclosed
Deal Type : Agreement